Literature DB >> 9135274

delta F508 in cystic fibrosis: willing but not able.

K W Southern1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9135274      PMCID： PMC1717108          DOI： 10.1136/adc.76.3.278

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  47 in total

Review 1.  Protein folding in the cell.

Authors:  M J Gething; J Sambrook
Journal:  Nature       Date:  1992-01-02       Impact factor: 49.962

2.  Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes.

Authors:  M L Drumm; D J Wilkinson; L S Smit; R T Worrell; T V Strong; R A Frizzell; D C Dawson; F S Collins
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

3.  The race for the cystic fibrosis gene.

Authors:  L Roberts
Journal:  Science       Date:  1988-04-08       Impact factor: 47.728

4.  Demonstration that CFTR is a chloride channel by alteration of its anion selectivity.

Authors:  M P Anderson; R J Gregory; S Thompson; D W Souza; S Paul; R C Mulligan; A E Smith; M J Welsh
Journal:  Science       Date:  1991-07-12       Impact factor: 47.728

5.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

6.  A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells.

Authors:  O Eidelman; C Guay-Broder; P J van Galen; K A Jacobson; C Fox; R J Turner; Z I Cabantchik; H B Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

7.  Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR).

Authors:  C E Bear; C H Li; N Kartner; R J Bridges; T J Jensen; M Ramjeesingh; J R Riordan
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

8.  Recombinant synthesis, purification, and nucleotide binding characteristics of the first nucleotide binding domain of the cystic fibrosis gene product.

Authors:  J Hartman; Z Huang; T A Rado; S Peng; T Jilling; D D Muccio; E J Sorscher
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

9.  Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation.

Authors:  S Sato; C L Ward; M E Krouse; J J Wine; R R Kopito
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

10.  Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker.

Authors:  L C Tsui; M Buchwald; D Barker; J C Braman; R Knowlton; J W Schumm; H Eiberg; J Mohr; D Kennedy; N Plavsic
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728
View more
  5 in total

Review 1.  Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.

Authors:  Kevin W Southern; Sanjay Patel; Ian P Sinha; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2018-08-02

2.  Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway.

Authors:  Hiroko Yaguchi; Naganari Ohkura; Maho Takahashi; Yuko Nagamura; Issay Kitabayashi; Toshihiko Tsukada
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

3.  Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

Authors:  Mica Skilton; Ashma Krishan; Sanjay Patel; Ian P Sinha; Kevin W Southern
Journal:  Cochrane Database Syst Rev       Date:  2019-01-07

4.  Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).

Authors:  Kevin W Southern; Jared Murphy; Ian P Sinha; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2020-12-17

5.  In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors.

Authors:  C Mueller; M S Strayer; J Sirninger; S Braag; F Branco; J-P Louboutin; T R Flotte; D S Strayer
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.